Conveying system of polypeptide-rare-earth material and preparation method and application

Abstract

The invention discloses a conveying system of a polypeptide-rare-earth material and a preparation method and application. The conveying system of the polypeptide-rare-earth material comprises a nanocluster (LDN), two different kinds of anticancer peptides (BIM and PMI) and one cyclic peptide iNGR. The nanocluster is formed through self-assembly of nano particles doped with lanthanide, and polypeptide BIM, PMI and iNGR are directly combined with the surface of the nanocluster through sulfydryl of cysteine. According to the conveying system of the polypeptide-rare-earth material, the resistanceof polypeptide medicine to protease hydrolysis is reinforced, in response to the reduction condition which exists in the tumor microenvironment, the polypeptide medicine is decomposed, growth of cancer cells is inhibited in vivo, and the material has good prospects in targeted treatment of the cancer.

Description

technical field [0001] The invention relates to the fields of biomedical materials and nanotechnology, in particular to a polypeptide-rare earth material delivery system and its preparation and application. Background technique [0002] Protein-protein interactions (PPIs) are a class of highly specific contacts between two or more proteins that result from metabolic reactions in almost all living processes. In the past few decades, there has been a large amount of basic research on the structure and biological function of proton pump inhibitors, and it was found that among the 650,000 PPIs in the human proteome, at least 40% are composed of protein globular domains and another composed of bond interactions between peptides or fragments of proteins. Therefore, these natural peptides or protein fragments can serve as a good framework for the development of peptide therapies. Even better, compared with traditional small molecules, peptides are less toxic, more specific, and e...

AI Technical Summary

Problems solved by technology

The reason for these prominent deletions is an inborn defect of the peptide: the peptide is membrane impermeable and biologically unstable

However, the clinical antitumor applications of various nanomedicines are always constrained by low tumor-specific localization and safety defects.

Although some delicate nanosystems can realize targeted anti-tumor therapy with biological safety, most of these nanocarriers have relatively complex structures and components, which largely rely on time-consuming and labor-intensive chemical processes.

Furthermore, after these laborious syntheses, there are always unavoidable residues of biologically unsafe organic reagents, resulting in reduced biocompatibility

Furthermore, due to the complex physical and chemical properties of peptides, including unfathomable topological structures and charge properties, nanodelivery systems inevitably suffer from the inherent problem of low drug loading.

To make matters worse, the complex chemical properties (hydrophobicity, charge, and redox) of peptides can also disrupt the homeostasis after coupling of colloidal nanoparticles.

The aggregation and precipitation of stable nanoparticles under physiological conditions will inevitably lead to the instability of particle circulation dynamics in vivo

Second, for cancer therapy, instability can lead to premature release of anticancer peptides and increased uptake by the reticuloendothelial system, resulting in ineffective delivery and off-target toxicity

Images